Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer
Abstract
Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 07, 2023
- Source ID
- 10.3390/ijerph20042903
Entities
People
- Craig D Shriver
- Leann A. Lovejoy
- Rachel E Ellsworth
- Svasti Haricharan
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Sanford Burnham Prebys Medical Discovery Institute
- Uniformed Services University of the Health Sciences